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Opinion Statement
Heart failure (HF) is a major cause of mortality and morbidity and one of the most fre-
quent reasons for hospital admission in the United States and Europe. Currently, more
than 50% of HF patients have a normal (N) left ventricular (LV) ejection fraction (EF)
(LVEF 950%). The main pathophysiologic processes involved in HFNEF are increased LV
stiffness and abnormal relaxation, resulting in impaired LV filling. Hypertension and
myocardial ischemia are the most common causes of HFNEF. Precipitating factors in-
clude volume overload, tachycardia, physical exercise, systemic stressors (such as fever
and infection), arrhythmia, increased salt intake, and use of nonsteroidal anti-inflam-
matory drugs. There is little evidence to guide treatment, as previously HFNEF patients
have been excluded from clinical trials on the basis of a normal LVEF. Survival improved
over time in patients with reduced (R) EF (HFREF) (LVEF G40%), reflecting the benefi-
cial effects of treatment in this phenotype. However, survival did not improve for
HFNEF patients. The approach to the treatment of HFNEF patients should focus on re-
ducing LV filling pressure, controlling hypertension, modifying ischemia, and improv-
ing LV relaxation. Therefore, diuretics are suitable for HFNEF patients to reduce
ventricular filling pressure. Hypertension can be treated by using multiple agents if
necessary. Drugs of particular interest and recommended to treat hypertension are cal-
cium channel blockers (CCBs) and antagonists of the renin-angiotensin-aldosterone
system, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor
blockers (ARBs), and aldosterone antagonists. Ischemic heart disease can be treated
with antiplatelet therapy, anticoagulants, and β-blockers. Heart rate control in atrial
fibrillation can be achieved with β-blockers and digoxin. Finally, ACE inhibitors and
ARBs could potentially decrease LV hypertrophy in hypertensive patients with HFNEF.
Introduction
Heart failure (HF) with normal (N) ejection fraction
(EF) constitutes nearly half of all HF patients and is as-
sociated with high morbidity and mortality [1]. This
phenotype is the predominant form of HF amongthe elderly, in women, and those with a history of hy-
pertension or diabetes. HFNEF patients have concen-
tric left ventricular (LV) remodeling with a normal
LV end diastolic volume, abnormalities of active relax-
ation, and increased passive ventricular stiffness [2–4].
The European Society of Cardiology (ESC) issued
new criteria for the diagnosis of HFNEF based on clin-
ical signs and/or symptoms of HF in the presence of
an LVEF 950% in a non-dilated LV (LV end-diastolic
volume G97 mL/m
2) and of abnormalities in LV dia-
stolic function/filling [5, 6￿￿]. The American College
of Cardiology (ACC) and the American Heart Associa-
tion (AHA) joint guidelines [7, 8] so far only recom-
mended blood pressure control, heart rate control,
central blood volume reduction, and alleviation of
myocardial ischemia as useful measures to treat
HFNEF patients.
However, despite the importance of HFNEF, the
pathophysiology and treatment of this phenotype re-
main poorly understood. Until now, large-scale clini-
c a lt r i a l si nH F N E Fp a t i e n t s( I r b e s a r t a ni nH Fw i t h
Preserved EF [I-Preserve] [9￿￿, Class I], Perindopril in
Elderly People with Chronic Heart Failure [PEP-CHF]
[10, Class I], Candesartan in Heart Failure-Assessment
of Reduction of Mortality and Morbidity [CHARM]-
Preserved [11, Class I], and Digitalis Investigation
Group Congestive Heart Failure [DIG-CHF] [12, Class
I]) failed to demonstrate effectiveness of any specific
therapy on mortality (Table 1). However, because
HFNEF patients are usually elderly, often with other
co-morbidities, quality of life and exercise capacity
may be more relevant endpoints than mortality.
In many studies, the effects of angiotensin-convert-
ing enzyme (ACE) inhibitors [13], β-blockers [14],
and angiotensin receptor blockers (ARBs) [15]h a v e
been assessed in HF patients with reduced (R) EF,
but few studies specifically evaluated the same com-
pounds in HFNEF patients. Pharmacologic treatment
of HFNEF patients is aimed to decrease blood pres-
sure, promote regression of LV hypertrophy, prevent
tachycardia, treat symptoms of congestion, and main-
tain atrial contraction as recommended by the ACC
and the AHA joint guidelines [7, 16 Class III]. These
guidelines target underlying HFNEF causes and are es-
timated to improve LV function and optimize hemo-
dynamics. β-blockers are usually used to improve LV
function, however they do not directly affect myocar-
dial relaxation. HFNEF patients may benefit from the
use of β-blockers, with reduction in heart rate, which
would reduce myocardial oxygen demand, increase
coronary perfusion time, and lengthen diastole [16].
In addition, β-blockers have been shown to reduce
blood pressure, to promote regression of LV hypertro-
phy, and to antagonize the excessive adrenergic stimu-
lation present in HF. Optimizing hemodynamics is
primarily achieved through reduction of cardiac pre-
load and afterload. ACE inhibitors and ARBs directly
affect myocardial relaxation and compliance by block-
ing angiotensin II receptors, thereby reducing intersti-
tial collagen deposition and fibrosis [17, 18]. ACE
inhibitors have shown to cause regression of LV hyper-
trophy, decrease blood pressure, and prevent or mod-
ify cardiac remodeling; these findings support the use
of ACE inhibitors in HFNEF patients [19, Class III].
Moreover, in the CHARM trial using the ARB candesar-
tan, beneficial effects were observed in HFNEF [11]
with reduction in the incidence of hospitalization for
CHF exacerbation (Table 1). However, in HFNEF
patients the ARB candesartan did not show a signifi-
cant mortality benefit [11].
Table 1. Completed large trials for HFNEF
DIG-PEF [12] CHARM-Preserved [11] I-PRESERVE [9￿￿] PEP-CHF [10]
Drug Digoxin Candesartan Irbesartan Perindopril
HFNEF patients, n 988 3023 3600 850
LVEF,% 945 940 940 945
Follow-up, mo 37 36.6 49.5 26.6
Outcome results
No effect on Mortality Mortality Mortality Mortality
Reduced Hospitalizations Hospitalizations Hospitalizations Hospitalizations
HFNEF heart failure with normal ejection fraction, LVEF left ventricular ejection fraction
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Overview The first large study that assessed the clinical
outcomes in HFNEF patients was the CHARM-
Preserved trial [11], aimed at evaluating the effect of
candesartan in patients with LVEF 940%. The median
duration of follow-up was 37.7 months. There was no
overall difference in the primary outcome of all-cause
death between the candesartan and the placebo group.
The number of HF hospitalizations was however sig-
nificantly lower. The latter effect was of similar magni-
tude to the one observed with enalapril in HFREF
patients in the Studies of Left Ventricular Dysfunction
(SOLVD) study [20]. However, more patients in the
candesartan group developed hypotension, hyperkale-
mia, or renal insufficiency. The HFNEF patients treated
with candesartan also showed a decreased incidence of
diabetes mellitus. Blockade of the renin-angiotensin
system with an ARB could therefore be beneficial for
HFNEF patients.
The PEP-CHF study [10] was a randomized double-
blind trial comparing placebo with perindopril. The
study included patients ≥70 years of age and 55%
were women. Median follow-up was 26.6 months
and all patients had a LVEF 945%. The trial showed
no decrease in mortality with the prolonged use of
perindopril. Patients who had a previous myocardial
infarction or with elevated systolic blood pressure
however appeared to benefit from perindopril. Never-
theless, the effects of perindopril on long-term mor-
bidity and mortality in HFNEF remain dubious
as the trial had inadequate power for its primary
endpoint.
The I-PRESERVE trial [9￿￿] recruited elderly patients,
predominantly female (60%), with an average age of
72 years and an LVEF 960%. The patients also frequent-
ly had a history of hypertension (88%) and electrocar-
diographic evidence of LV hypertrophy. The prevalence
of previous myocardial infarction was low. The I-PRE-
SERVE trial assigned HFNEF patients to irbesartan or
placebo and demonstrated no decrease in mortality or
hospitalizations for cardiovascular causes.
DIG-PEF [12] was a randomized, double-blind,
placebo-controlled trial that evaluated the effects of di-
goxin on all-cause mortality and on hospitalizations
in patients with LVEF 945% and with normal sinus
rhythm. Average follow-up was 37 months. The trial
revealed that 23.4% of HFNEF patients died during
follow-up because of cardiovascular causes (70%)
and non-cardiovascular causes (30%). The study sug-
gested that digoxin reduced hospitalization over the
first 24 months of treatment but that it had no effect
on mortality.
Characteristics of patients recruited in I-PRESERVE
and PEP-CHF were similar. Characteristics of patients
recruited in DIG-PEF and CHARM-Preserved were
however different, especially in terms of HF etiology,
age and gender. In addition, patients from DIG-PEF
and CHARM-Preserved had a lower LVEF compared
to patients from I-PRESERVE and PEP-CHF. Further-
more, in all these studies diastolic LV dysfunction
was poorly characterized and this could have led to
inclusion of numerous patients whose exercise intol-
erance was unrelated to HF but caused by decondi-
tioning because of co-morbidities such as arthrosis
deformans, chronic obstructive pulmonary disease,
and obesity.
Finally, the Study of the Effects of Nebivolol Inter-
vention on Outcomes and Rehospitalization in
Seniors with heart failure (SENIORS) trial should be
mentioned as it is the first large HF outcome trial re-
stricted to a population over 70 years of age and as
it specifically looked at a subgroup of patients with a
LVEF 935% [21]. The SENIORS trial showed that treat-
ment with the β-blocker nebivolol decreased cardio-
vascular morbidity and that this effect did not differ
between patients with a LVEF G35% and a LVEF
935%. Favorable effects of nebivolol treatment on
LV remodeling such as a decrease in LV end-systolic
volume and an increase in LVEF were however limited
to patients presenting with a LVEF 935%. Beneficial
effects of β-blocker treatment in older HF patients
are in line with previous trials on the use of β-blockers
in HF such as the Carvedilol Prospective Randomized
Cumulative Survival (COPERNICUS) trial (patients ≥
65 years) [22], the Cardiac Insufficiency Bisoprolol
Study (CIBIS II) trial (patients ≥71 years) [23], and
the Metoprolol CR/XL Randomised Intervention Trial
in Congestive Heart Failure (MERIT-HF) trial (patients
969 years) [24], which all showed a reduction in all-
cause mortality or cardiovascular hospitalization in el-
derly patients [21, 25].
Unequal Outcome of Trials in HFNEF and HFREF
There are LV structural and functional similarities and
differences between HFNEF and HFREF patients. The
similarities include an increased LV mass and an in-
creased LV end-diastolic pressure [5, 26]. The differen-
ces between the two phenotypes involve both LV
geometry and LV function and could account for the
unequal outcome of trials in HFNEF and HFREF de-
28 Coronary Artery Diseasespite use of similar pharmacologic agents. HFREF is
characterized by LV dilatation, eccentric LV remodel-
ing, and abnormal systolic and diastolic function,
whereas HFNEF is characterized by a normal LVEF
and concentric LV remodeling with increased LV wall
thickness and decreased LV volume/mass ratio [27,
28]. These structural and functional differences were
also evident at the ultrastructural level. LV myocardi-
um of HFNEF patients has larger cardiomyocytes, less
interstitial fibrosis, and preserved myofilamentary
density. When cardiomyocytes were isolated from LV
biopsies, cardiomyocyte resting tension (Fpassive)w a s
also higher in HFNEF compared to HFREF [27, 29].
Because of these anatomic and histologic differences
between LV myocardium in HFNEF and HFREF, LV
remodeling also follows a distinct course in both phe-
notypes. In HFREF, LV remodeling mainly evolves to
progressive LV dilatation and further reduction of LV
systolic function. In HFNEF, this evolution is absent
as disease progression is characterized by further devel-
opment of concentric LV hypertrophy and exacerbation
of abnormal diastolic function. Unequal outcome of
trials using similar pharmacologic compounds is there-
fore again no surprise as the ultimate goal of treatment
in terms of preventing unfavorable myocardial remod-
eling is vastly different in both conditions.
This concept was nicely illustrated by a study that
looked at the myocardial effects of β-blocker treatment
in HFNEF and HFREF patients. This study investigated
the effects of β-blocker therapy on myofilamentary
function of cardiomyocytes isolated from endomyocar-
dial biopsies of HFNEF or HFREF patients. The study
observed a significantly higher Fpassive in HFNEF
patients treated with β-blockers compared to HFNEF
patients without β-blockers and failed to report a sim-
ilar finding in HFREF patients. Even after in vitro
administration of protein kinase A (PKA), Fpassive
remained significantly higher in HFNEF patients treated
with β-blockers compared to HFNEF patients without
β-blockers, indicating that β-blocker therapy had dis-
tinct effects on myofilamentary function in HFNEF
and HFREF patients [29].
Treatment
Diet and Lifestyle
& According to the ESC guidelines, lifestyle modifications [6￿￿, Class
III] are recommended to reduce the risk of all forms of cardiovascular
disease. These lifestyle modifications include the following:
& Weightloss:exercisehelpstoachieveandmaintainahealthyweightand
control diabetes, elevated cholesterol, and high blood pressure [30].
& Optimal blood pressure control.
& Diet and nutrition: eating a low-fat, low-sodium diet. Randomized
clinicaltrialswithlow-saltandfluid-restricteddietshowedthatfollowing
a 6-month period of an individually prescribed salt- and fluid restricted-
diet, patients with mild to moderate HF showed clinical improvements
with an absence of edema and fatigue, leading to an improvement in
New York Heart Association (NYHA) class and quality of life [30].
& Smoking cessation: smoking is a major risk factor for HF. No pro-
spective studies have assessed the effects of smoking cessation in
patients with HF. Observational data support the association be-
tween continued smoking and increased HF mortality and rates of
hospitalizations as compared to non-smokers, recent ex-smokers,
and longer ex-smokers [31, 32].
& Alcohol may have a negative inotropic effect, and may be associated
with an increase in blood pressure [31]. Alcohol intake should be
limited to 10 to 20 g/d (1–2 glasses of wine/day).
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that directly or indirectly worsen the diastolic function, such as
high blood pressure, diabetes, and hypercholesterolemia, are
important in reducing the risk of subsequent HFNEF [7, 30 Class
III].
Pharmacologic Treatment
& To date, no pharmacologic therapy was demonstrated to reduce
mortality and morbidity in HFNEF patients. In many large, ran-
domized, controlled clinical trials, researchers have assessed the
beneficial effects of ACE inhibitors, β-blockers, and ARBs in
HFREF patients, but these effects have not been established in
HFNEF patients. Treatment recommendations are derived mainly
from the large evidence-based trials that existed for management
of HFREF [8, Class I] or are based largely on the results of small,
non-randomized studies, clinical experience, and pathophysio-
logic reasoning [33, Class III]. Recently, two large-scale HFNEF
trials have reported their disappointing results: in the CHARM-
Preserved trial, the ARB candesartan produced a modest reduction
in hospitalizations for HF but had no effect on mortality [11];
in PEP-CHF, the ACE-inhibitor perindopril had similar effects
[10].
& Aldosterone antagonists reduce myocardial fibrosis [34]. In addition,
aldosterone antagonists lower blood pressure and directly affect
myocardial relaxation, which is also useful in the treatment of dia-
stolic LV dysfunction in HFNEF patients.
& The reduction in heart rate and prevention of tachycardia with β-
blocker treatment has several benefits on diastolic function, includ-
ing a prolongation of diastole and the LV filling time and an im-
provement of ischemia. In addition, β-blockers have demonstrated
benefits in reducing blood pressure and myocardial ischemia, pro-
moting regression of LV hypertrophy, and antagonizing the excessive
adrenergic stimulation during HF. β-blockers have been associated
with decreased HF symptoms in HFNEF patients [35, Class II].
& Calcium channel blockers have been shown to accelerate ven-
tricular relaxation in patients with hypertrophic cardiomyopathy
and have been reported to directly improve diastolic LV function
by decreasing cardiomyocyte cytoplasmic calcium concentration
[36].
& Restriction of sodium intake and the administration of diuretics
may be beneficial through reduction of LV ventricular filling pres-
sures. They are also useful in treating hypertension, which is a
common trigger for worsening HFNEF. In the Hong Kong Diastolic
Heart Failure, diuretics alone appeared to be effective in reducing
symptoms and improving quality of life in HFNEF patients [37].
The goals for pharmacologic treatment of HFNEF are summarized
in Table 2.
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Percutaneous Coronary Intervention and Coronary Bypass Surgery
& When the cause of HFNEF is ischemic, standard pharmacologic treat-
ment would be the use of nitrates, calcium channel blockers, and β-
blockers. However, both a percutaneous coronary interventional tech-
nique and coronary artery bypass surgery should be considered in se-
lectedHFpatientswithcoronaryarterydisease[38].Theirusewillresult
in better outcome at lower cost (quality of life improvement) [39].
Valvular Replacement
& If the cause of HFNEF is valvular heart disease (usually aortic ste-
nosis), aortic valve replacement is mandatory. Surgical replacement
or repair of valves relieves symptoms and improves quality of life in
HFNEF [40]. Relief may be gradual, in parallel with remodeling of
Table 2. Goals for pharmacologic treatment of HFNEF
Drug class Goal of treatment
ACE inhibitor Hypertension
LV blood pressure
LV hypertrophy
LV relaxation
Myocardial fibrosis
Myocardial ischemia
ARB Hypertension
LV hypertrophy
LV filling pressures
Myocardial fibrosis
CCB Heart rate
Hypertension
LV hypertrophy
Exercise capacity
Myocardial ischemia
β-Blocker Heart rate
Hypertension
LV hypertrophy
Myocardial ischemia
Tachycardia
Diuretic Hypertension
Myocardial ischemia
LV filling pressure
LV diastolic volume
Aldosterone antagonist Myocardial fibrosis
LV hypertrophy
Digoxin Decrease heart rate in atrial fibrillation patients
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, CCB calcium channel blocker, HFNEF heart failure with normal ejec-
tion fraction, LV left ventricular
Treatment of Heart Failure Hamdani and Paulus 31the heart and regression of LVH following the correction of the ab-
normal loading conditions imposed by the LV pressure overload.
Emerging Pharmacological Therapies
In the ongoing trials Treatment of Preserved Cardiac Function HF with an
Aldosterone Antagonist (TOPCAT) and Aldosterone in Diastolic HF
(ALDO-DHF), the role of spironolactone versus placebo is being studied to
elucidate if an anti-fibrotic intervention strategy is adequate to improve the
outcome in HFNEF. In the Japanese diastolic HF trial (J-DHF), the efficacy
of β- b l o c k e r si sb e i n gs t u d i e d ,a n di nt he Evaluating the Effectiveness of
Sildenafil at Improving Health Outcomes and Exercise Ability in People
With Diastolic Heart Failure (RELAX) trial, sildenafil (phosphodiesterase-5
inhibition) is being studied to improve clinical status and exercise capacity
in HFNEF. In addition, smaller studies are investigating the effects of sta-
tins, ivabradine and cardiac resynchronization therapy (or biventricular
pacing), which may also be beneficial for HFNEF patients.
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